Cargando…

Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study

BACKGROUND: In China, no multicenter double-blinded prospective randomized controlled study on labor induction has been conducted till now. This study is to evaluate the efficacy and safety of intravaginal accurate 25-μg misoprostol tablets for cervical ripening and labor induction in term pregnancy...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Zhu, Hao-Ping, Fan, Jian-Xia, Yu, Hong, Sun, Li-Zhou, Chen, Lian, Chang, Qing, Zhao, Nai-Qing, Di, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736884/
https://www.ncbi.nlm.nih.gov/pubmed/26481739
http://dx.doi.org/10.4103/0366-6999.167299
_version_ 1782413370553532416
author Zhang, Yu
Zhu, Hao-Ping
Fan, Jian-Xia
Yu, Hong
Sun, Li-Zhou
Chen, Lian
Chang, Qing
Zhao, Nai-Qing
Di, Wen
author_facet Zhang, Yu
Zhu, Hao-Ping
Fan, Jian-Xia
Yu, Hong
Sun, Li-Zhou
Chen, Lian
Chang, Qing
Zhao, Nai-Qing
Di, Wen
author_sort Zhang, Yu
collection PubMed
description BACKGROUND: In China, no multicenter double-blinded prospective randomized controlled study on labor induction has been conducted till now. This study is to evaluate the efficacy and safety of intravaginal accurate 25-μg misoprostol tablets for cervical ripening and labor induction in term pregnancy in nulliparous women. METHODS: This was a double-blinded, prospective randomized controlled study including nulliparous women from 6 university hospitals across China. Subjects were randomized into misoprostol or placebo group with the sample size ratio set to 7:2. Intravaginal 25-μg misoprostol or placebo was applied at an interval of 4 h (repeated up to 3 times) for labor induction. Primary outcome measures were the incidence of cumulative Bishop score increases ≥3 within 12 h or vaginal delivery within 24 h. Safety assessments included the incidences of maternal morbidity and adverse fetal/neonatal outcomes. RESULTS: A total of 173 women for misoprostol group and 49 women for placebo were analyzed. The incidence of cumulative Bishop score increases ≥3 within 12 h or vaginal delivery within 24 h was higher in the misoprostol group than in the placebo (64.2% vs. 22.5%, relative risk [RR]: 2.9, 95% confidence interval [CI]: 1.4–6.0). The incidence of onset of labor within 24 h was significantly higher in the misoprostol group than in the placebo group (48.0% vs. 18.4%, RR: 2.6, 95% CI: 1.2–5.7); and the induction-onset of labor interval was significantly shorter in the misoprostol group (P = 0.0003). However, there were no significant differences in the median process time of vaginal labor (6.4 vs. 6.8 h; P = 0.695), incidence (39.3% vs. 49.0%, RR: 0.8, 95% CI: 0.4–1.5) and indications (P = 0.683) of cesarean section deliveries, and frequencies of maternal, fetal/neonatal adverse events between the groups. CONCLUSION: Intravaginal misoprostol 25 μg every 4 h is efficacious and safe in labor induction and cervical ripening.
format Online
Article
Text
id pubmed-4736884
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-47368842016-04-04 Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study Zhang, Yu Zhu, Hao-Ping Fan, Jian-Xia Yu, Hong Sun, Li-Zhou Chen, Lian Chang, Qing Zhao, Nai-Qing Di, Wen Chin Med J (Engl) Original Article BACKGROUND: In China, no multicenter double-blinded prospective randomized controlled study on labor induction has been conducted till now. This study is to evaluate the efficacy and safety of intravaginal accurate 25-μg misoprostol tablets for cervical ripening and labor induction in term pregnancy in nulliparous women. METHODS: This was a double-blinded, prospective randomized controlled study including nulliparous women from 6 university hospitals across China. Subjects were randomized into misoprostol or placebo group with the sample size ratio set to 7:2. Intravaginal 25-μg misoprostol or placebo was applied at an interval of 4 h (repeated up to 3 times) for labor induction. Primary outcome measures were the incidence of cumulative Bishop score increases ≥3 within 12 h or vaginal delivery within 24 h. Safety assessments included the incidences of maternal morbidity and adverse fetal/neonatal outcomes. RESULTS: A total of 173 women for misoprostol group and 49 women for placebo were analyzed. The incidence of cumulative Bishop score increases ≥3 within 12 h or vaginal delivery within 24 h was higher in the misoprostol group than in the placebo (64.2% vs. 22.5%, relative risk [RR]: 2.9, 95% confidence interval [CI]: 1.4–6.0). The incidence of onset of labor within 24 h was significantly higher in the misoprostol group than in the placebo group (48.0% vs. 18.4%, RR: 2.6, 95% CI: 1.2–5.7); and the induction-onset of labor interval was significantly shorter in the misoprostol group (P = 0.0003). However, there were no significant differences in the median process time of vaginal labor (6.4 vs. 6.8 h; P = 0.695), incidence (39.3% vs. 49.0%, RR: 0.8, 95% CI: 0.4–1.5) and indications (P = 0.683) of cesarean section deliveries, and frequencies of maternal, fetal/neonatal adverse events between the groups. CONCLUSION: Intravaginal misoprostol 25 μg every 4 h is efficacious and safe in labor induction and cervical ripening. Medknow Publications & Media Pvt Ltd 2015-10-20 /pmc/articles/PMC4736884/ /pubmed/26481739 http://dx.doi.org/10.4103/0366-6999.167299 Text en Copyright: © 2015 Chinese Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Zhang, Yu
Zhu, Hao-Ping
Fan, Jian-Xia
Yu, Hong
Sun, Li-Zhou
Chen, Lian
Chang, Qing
Zhao, Nai-Qing
Di, Wen
Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study
title Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study
title_full Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study
title_fullStr Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study
title_full_unstemmed Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study
title_short Intravaginal Misoprostol for Cervical Ripening and Labor Induction in Nulliparous Women: A Double-blinded, Prospective Randomized Controlled Study
title_sort intravaginal misoprostol for cervical ripening and labor induction in nulliparous women: a double-blinded, prospective randomized controlled study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736884/
https://www.ncbi.nlm.nih.gov/pubmed/26481739
http://dx.doi.org/10.4103/0366-6999.167299
work_keys_str_mv AT zhangyu intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT zhuhaoping intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT fanjianxia intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT yuhong intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT sunlizhou intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT chenlian intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT changqing intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT zhaonaiqing intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy
AT diwen intravaginalmisoprostolforcervicalripeningandlaborinductioninnulliparouswomenadoubleblindedprospectiverandomizedcontrolledstudy